PDF(Pubmed)
Abstract：
There is a dearth of studies investigating whether the combination of low-intensity statins with ezetimibe can reduce the risk of diabetes in patients requiring statin therapy. Therefore, we aimed to evaluate the effects of combination therapy on the prevention of glycated hemoglobin (HbA1c) elevation in patients without diabetes. Sixty-eight patients were randomly assigned in a 1:1 ratio to receive a combination of low-intensity rosuvastatin (5 mg/day) and ezetimibe (10 mg/day) or high-intensity rosuvastatin (20 mg/day). The primary endpoint was the absolute difference in the HbA1c levels at 12 weeks. The HbA1c level showed an overall elevation of 0.11% at 12 weeks compared to that at baseline (mean ± standard deviation: 5.78 ± 0.3%, 95% confidence interval [CI]: 5.86-6.07, p = 0.044). The HbA1c levels did not differ between the groups at 12 weeks (least square mean difference: 0.001, 95% CI: 0.164-0.16, p = 0.999). Our study found that the combination of low-intensity rosuvastatin and ezetimibe did not yield significant differences in HbA1c levels compared to high-intensity rosuvastatin alone after 12 weeks in patients without diabetes. This suggests that the combination of low-intensity rosuvastatin and ezetimibe may not be an effective strategy for preventing HbA1c elevation in patients without diabetes requiring statins.
摘要：
缺乏研究低强度他汀类药物与依泽替米贝的组合是否可以降低需要他汀类药物治疗的患者患糖尿病的风险的研究。因此,我们旨在评估联合治疗对预防非糖尿病患者糖化血红蛋白(HbA1c)升高的效果.68例患者以1：1的比例随机分配，接受低强度瑞舒伐他汀（5mg/天）和依泽替米贝（10mg/天）或高强度瑞舒伐他汀（20mg/天）的联合治疗。主要终点是12周时HbA1c水平的绝对差异。与基线相比，HbA1c水平在12周时显示出0.11％的总体升高（平均值±标准偏差：5.78±0.3％，95%置信区间[CI]：5.86-6.07，p=0.044)。在12周时，两组之间的HbA1c水平没有差异（最小均方差异：0.001，95％CI：0.164-0.16，p=0.999）。我们的研究发现，在没有糖尿病的患者中，低强度瑞舒伐他汀和依泽替米贝的组合与单独使用高强度瑞舒伐他汀相比，HbA1c水平没有显著差异。这表明低强度瑞舒伐他汀和依泽替米贝的组合可能不是预防需要他汀类药物的无糖尿病患者HbA1c升高的有效策略。
